Literature DB >> 21111679

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

Thierry Buclin1, Nicolas Widmer, Jerome Biollaz, Laurent A Decosterd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21111679     DOI： 10.1016/S1470-2045(10)70258-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Monitoring drug therapy.

Authors:  Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

Authors:  Verena Gotta; Nicolas Widmer; Michael Montemurro; Serge Leyvraz; Amina Haouala; Laurent A Decosterd; Chantal Csajka; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

Review 3.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

Review 4.  The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib.

Authors:  Thierry Buclin; Yann Thoma; Nicolas Widmer; Pascal André; Monia Guidi; Chantal Csajka; Laurent A Decosterd
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.